目的 探究在老年非小细胞肺癌(Non-small Cell Lung Cancer,NSCLC)患者中采用程序性死亡蛋白-1(Programmed Death Protein-1,PD-1)抑制剂联合安罗替尼治疗的临床效果和安全性.方法 单纯随机选取2021年10月—2023年10月宿迁高新区人民医院收治的80例老年NSCLC患者为研究对象,按随机数字表法分为两组,各40例.对照组予以PD-1抑制剂治疗,观察组联合安罗替尼治疗.比较两组的临床效果、肿瘤标志物水平、血清血管内皮生长因子(Vascular Endothelial Growth Factor,VEGF)及基质金属蛋白酶-2(Matrix Metalloproteinase-2,MMP-2)水平、免疫功能与安全性.结果 观察组客观缓解率(Objective Response Rate,ORR)、疾病控制率(Disease Control Rate,DCR)均高于对照组,差异有统计学意义(P均<0.05).治疗前,两组肿瘤标志物水平、血清VEGF及MMP-2水平、免疫功能对比,差异无统计学意义(P均>0.05);治疗后,观察组肿瘤标志物水平、VEGF及MMP-2水平均低于对照组,免疫功能优于对照组,差异有统计学意义(P均<0.05);两组不良反应对比(40.00%vs 47.50%),差异无统计学意义(χ2=0.335,P=0.563).结论 PD-1抑制剂联合安罗替尼治疗老年NSCLC患者可有效降低肿瘤标志物、VEGF及MMP-2水平,改善免疫功能,且安全性高.
Clinical Effect and Safety Analysis of PD-1 Inhibitor Combined with Anlo-tinib in the Treatment of Elderly Patients with Non-small Cell Lung Can-cer
Objective To investigate the clinical efficacy and safety of programmed death protein-1(PD-1)inhibitor combined with anlotinib in elderly patients with non-small cell lung cancer(NSCLC).Methods A total of 80 elderly patients with NSCLC admitted to Suqian High-tech Zone People's Hospital from October 2021 to October 2023 were simple randomly selected as study objectives and divided into two groups according to the random number table method,with 40 cases in each group.The control group was treated with PD-1 inhibitor,and the observation group was treated with anlotinib.The clinical effects,tumor marker levels,serum vascular endothelial growth factor(VEGF)and matrix metalloproteinase-2(MMP-2)levels,immune function and safety were compared between the two groups.Results The objective response rate(ORR)and disease control rate(DCR)in the observation group were higher than those in the control group,and the differences were statistically significant(both P<0.05).Before treatment,there were no significant differences in tumor marker levels,serum VEGF and MMP-2 levels,and immune function between the two groups(all P>0.05).After treatment,the levels of tumor markers,VEGF and MMP-2 in the observation group were lower than those in the control group,and the immune function was better than that in the control group,the dif-ferences were statistically significant(all P<0.05).There was no significant difference in adverse reactions between the two groups(χ2=0.335,P=0.563).Conclusion PD-1 inhibitor combined with anlotinib can effectively reduce the levels of tumor markers,VEGF and MMP-2 and improve immune function in elderly patients with NSCLC,with high safety.
Senile non-small cell lung cancerProgrammed death protein-1 inhibitorAnlotinibTumor markersImmune functionSecurity
万方数据
维普
